FAKE DIETARY SUPPLEMENTS

The dangers of purchasing fake supplements:

• You waste money and resources on a product that will not give the desired result

• They may contain inaccurate levels of the active ingredients in the supplement, which may pose a risk to you

• You could have a life threatening allergic reaction to one of the ingredients not listed on the bottle

• The unlisted ingredients may also interact with other medications you may be taking, which can cause more complex health issues

While there are limited resources in detecting fake supplements at the consumer level, here are some points to keep in mind when trying to verify these supplements without product verification technology.How to detect these fake supplements:

• The dietary supplement claims to be a good alternative to FDA approved drugs

• The products are strongly promoted via email but are hardly available in stores (Be wary even in trusted stores)

• The manufacturer makes claims that may seem too good to be true

• There are obvious typos, poor quality packaging, or the odor is different

It is important that consumers become more aware of issues associated with purchasing fake dietary supplements and the ways to help detect fake supplement

FDA APPROVED DRUGS FOR CARDIALOGY

Drugs Approved in 2015

Prestalia (perindopril arginine and amlodipine besylate); Symplmed Pharmaceuticals; For the treatment of hypertension, Approved January 2015

Savaysa (edoxaban); Daiichi Sankyo; For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015

Drugs Approved in 2014

Epanova (omega-3-carboxylic acids); AstraZeneca; For the treatment of severe hypertriglyceridemia, Approved May 2014

Zontivity (vorapaxar); Merck; For the reduction of thrombotic cardiovascular events, Approved May 2014

Drugs Approved in 2013

Adempas (riociguat); Bayer Healthcare Pharmaceuticals; For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension, Approved October 2013

Kynamro (mipomersen sodium); Genzyme; For the treatment of homozygous familial hypercholesterolemia, Approved January 2013

Liptruzet (ezetimibe and atorvastatin); Merck; For the treatment of hyoerlipidemia, Approved May 2013

Nymalize (nimodipine); Arbor Pharmaceuticals; For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013

Opsumit (macitentan); Actelion Pharmaceuticals; For the treatment of pulmonary arterial hypertension, Approved October 2013

Varithena (polidocanol injectable foam); BTG plc; For the treatment of varicose veins, November 2013

Drugs Approved in 2012

Eliquis (apixaban); Bristol-Myers Squibb; For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation, Approved December 2012

Juxtapid (lomitapide); Aegerion Pharmaceuticals; For the treatment of homozygous familial hypercholesterolemia, Approved December of 2012

Vascepa (icosapent ethyl); Amarin Pharmaceuticals; For the treatment of hypertriglyceridemia, Approved July of 2012

Drugs Approved in 2011

Brilinta (ticagrelor); AstraZeneca; For the reduction of thrombotic events in patients with acute coronary syndrome, Approved July 2011

Edarbi (azilsartan medoxomil); Takeda; For the treatment of hypertension, Approved February 2011

Edarbyclor (azilsartan medoxomil and chlorthalidone); Takeda; For the treatment of hypertension, Approved December of 2011

Xarelto (rivaroxaban); Bayer; For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011

Xarelto (rivaroxaban); Janssen Pharmaceuticals; For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation, Approved November 2011

Drugs Approved in 2010

Amturnide (aliskiren + amlodipine + hydrochlorothiazide); Novartis; For the treatment of uncontrolled hypertension, Approved December 2010

Pradaxa (dabigatran etexilate mesylate); Boehringer Ingelheim; For the risk reduction of stroke and embolism due to atrial fibrillation, Approved October 2010

Tekamlo (aliskiren + amlodipine); Novartis; For the treatment of hypertension, Approved August 2010

Tribenzor (olmesartan medoxomil + amlodipine + hydrochlorothiazide); Daiichi Sankyo; For the treatment of hypertension, Approved July 2010

    WORLD TUBERCULOSIS DAY,MARCH 24

Global impact of TB

TB occurs in every part of the world. In 2013, the largest number of new TB cases occurred in the South-East Asia and Western Pacific Regions, accounting for 56% of new cases globally. However, Africa carried the greatest proportion of new cases per population with 280 cases per 100 000 population in 2013.

In 2013, about 80% of reported TB cases occurred in 22 countries. Some countries are experiencing a major decline in cases, while in others the numbers are dropping very slowly. Brazil and China for example, are among the 22 countries that showed a sustained decline in TB cases over the past 20 years. In the last decade, the TB prevalence in Cambodia fell by almost 50%.

On World TB Day, 24 March

 WHO is calling for new commitments and new action in the global fight against tuberculosis – one of the world’s top infectious killers.

There has been tremendous progress in recent years, and the world is on track to meet the Millennium Development Goal of reversing the spread of TB by 2015. But this is not enough. In 2013, 9 million people fell ill with TB and 1.5 million died.

Clearly, we all need to do more.

Last May, at the World Health Assembly, governments agreed on ambitious new 20-year (2016-2035) strategy to end the global TB epidemic.

WHO’s End TB Strategy envisions a world free of TB with zero deaths, disease and suffering. It sets targets and outlines actions for governments and partners to provide patient-centred care, pursue policies and systems that enable prevention and care, and drive research and innovations needed to end the epidemic and eliminate TB.

On World TB Day 2015, WHO calls on governments, affected communities, civil society organizations, health-care providers, and international partners to join the drive to roll out this strategy and to reach, treat and cure all those who are ill today.

24 March 2015 - the day to change gear and speed up global efforts to end TB altogether.

                       HEPATITIS C DRUG IN INDIA

Dr Reddy's Laboratories  on Monday entered into an agreement with Hetero to

 distribute and market generic version of US-firm Gilead Sciences' Hepatitis C 

drug under the brand 'Resof' in India. "The company has entered into an 

agreement with Hetero, under which Dr Reddy's has been licensed to distribute 

and market Sofosbuvir 400 mg tablets indicated in treatment of chronic 

Hepatitis C under the brand 'Resof' in India," the Hyderabad-based drug major

 said in a BSE filing. Sofosbuvir is a medicine used for chronic Hepatitis C 

infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi

. Hetero had signed a non-exclusive agreement with Gilead Sciences to 

manufacture and sell its Hepatitis medicines. "With the diagnosis rates for

 Hepatitis C in India being abysmally low, Dr Reddy's will make a significant

 difference in the diagnosis and treatment of this disease," the company said.

 "The launch of Resof is in line with Dr Reddy's philosophy of innovative 

medicine at a at an affordable price and will provide significant relief to 

patients, resulting in potential cure and a high barrier to resistance at an

 affordable price for those living with Hepatitis C," Dr Reddy's Laboratories 

Co-Chairman and CEO G V Prasad said. Gilead Sciences also signed non-

exclusive licensing agreements with Zydus Cadila and Natco Pharma   to 

manufacture Sofosbuvir for distribution in 91 developing countries including

 India. Earlier this month, Natco Pharma launched the drug in Nepal.